Aims and objectives: To present the findings of an integrative literature review of the evidence for the clinical management of delirium in patients with advanced cancer.
. This means that end-of-life concerns, such as preferred place of death, are real and valid for those diagnosed with advanced cancer. For example, although most people would prefer to die at home rather than in hospital (National Audit Office, 2008) , delirium can result in longer hospital stays (Ljubisavljevic & Kelly, 2003) , meaning patients may not be able to die in their preferred place. Moreover family members and carers generally provide the most care for their loved ones experiencing delirium which causes distress (Namba et al., 2007) , which is often exacerbated as delirious patients are more likely to be noncompliant and risk putting themselves or others in danger (for example by pulling out IV lines/ catheters) and being aggressive.
In view of this, a need to examine the evidence for the clinical management of delirium in patients with advanced cancer was identified, in order to determine how it can be best managed. The aim of this review was to examine evidence for pharmacological and nonpharmacological treatments for delirium in patients with advanced cancer to determine the evidence base for practice and to highlight gaps in knowledge.
| BACKGROUND
One of the most challenging aspects of end-of-life care, and a reason why many patients stay in and die hospital, is poor symptom control. Effective amelioration of symptoms including delirium, pain and nausea can help a patient to have a "good death" (de Jong & Clarke, 2009) . Although guidelines exist for the general and more specific management of delirium in patients with cancer (CCO, 2010 , NICE, 2015 , Western Australia Cancer & Palliative Care Network, 2010 , the guidance concerning treatment in patients with advanced cancer is limited, in part because of the limited evidence available.
The treatment and medication patients may receive as part of their cancer treatment can mean the standard approach to treating delirium is less effective.
Delirium is defined as a neurocognitive disorder characterised by a disturbance in attention and cognition, which can result from another medical condition (or from multiple aetiologies) for example pyrexia and malnutrition. The condition develops over a short period of time and cannot be explained by any another neurocognitive disorder (Diagnostic and Statistical Manual of Mental Disorders-V, 2013) . Delirium can manifest in a number of ways (Table 1) , and in practice, it is often nurses who recognise the symptoms when they first present. A variety of tools exist which can be used to help identify and diagnose the condition. For example, the National Institute for Health and Care Excellence (NICE, 2010) and often used in screening. Despite the availability of these tools however, the rate of detection of delirium in patients in practice is low. Ryan et al. (2013) found that nurses identified 63.6% of patients with delirium as confused or delirious; however, only 43.6% of those patients had the observation they were confused recorded in their notes. In a study of patients with advanced cancer, it was found that the overall detection rate in patients with terminal cancer by any member of the palliative team was 44.9% and the detection rate of the hypoactive subtype was only 20.5%, significantly lower than that of the hyperactive/mixed subtypes (Fang et al., 2008) .
Although the term delirium is widely used, there are distinct subtypes of delirium which are based on their clinical presentation. They are as follows: hyperactive, hypoactive and mixed, and delirium with • There is a lack of evidence to inform the management of delirium in patients with advanced cancer.
• The lack of evidence for the management of delirium in patients with advanced cancer means that patients, their families and carers, may not be receiving the most appropriate care.
Key findings
• Available research on the clinical management of delirium in advanced cancer is limited and of variable quality.
• A number of pharmacological and nonpharmacological interventions have been used to treat delirium in patients with advanced cancer; however, the evidence base for practice is limited.
How should these findings be used?
• These findings highlight the need for further investigation of the treatment of delirium in advanced cancer.
• Provide insights for nurses and other professionals on the effectiveness of the treatments currently in use. (Grover et al., 2014) . In other studies, the mixed type of delirium was most common (Kim et al., 2015; Peterson et al., 2006) .
Patients with hyperactive delirium are often restless, agitated and hypervigilant and experience perceptual disturbances and delusions, whereas patients with hypoactive delirium demonstrate lethargy and minimal spontaneous movement (Fong, Tulebaev, & Inouye, 2009; Grover et al., 2014) . The identification of different subtypes raises the issue of whether they should be treated as separate conditions, especially noting that patients experiencing hypoactive and mixed types of delirium have a poorer prognosis than those with hyperactive delirium (Kim et al., 2015) , suggesting different treatment approaches may be needed.
Estimates for total cancer deaths in 2012 were 8.2 million (about 22,000 cancer deaths a day), and by 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths (American Cancer Society, 2015) . The prevalence of delirium in patients with terminal cancer ranges from 28%-85% (de la Cruz et al., 2015; Massie, Holland, & Glass, 1983; Minagawa, Uchitomi, Yamawaki, & Ishitani, 1996) . This large variation may be a result of the difficulties involved in accurately identifying the symptoms of the different subtypes of delirium (particularly hypoactive delirium), misdiagnosis or a lack of the training staff need to make an assessment. Patients with cancer are at particular risk of developing delirium for a number of reasons, including exposure to certain drugs (opioids, corticosteroids and benzodiazepines) (Gaudreau, Gagnon, Harel, Roy, & Tremblay, 2005) , and the presence of bone metastases and haematological malignancies (Ljubisavljevic & Kelly, 2003) . In a recent literature review, it was concluded that there needs to be a greater understanding of delirium in palliative care, including its pathophysiology and causation, as well as its treatment (Grassi et al., 2015) .
| CURRENT CLINICAL MAN AGEMENT
Current approaches to the care of people with delirium involve nonpharmacological and pharmacological management. Nonpharmacological interventions are recommended such as nurses ensuring there is a clock visible in clinical areas and explaining to patients where they are and introducing themselves and other staff members, helping to keep patients orientated to time and place (NICE, 2010) . Preventing precipitating factors such as constipation and dehydration can also help (NICE, 2010) , and this entails nursing staff planning care to ensure patients are mobilised, encouraged to drink and that bowel movements are monitored. Pharmacologically, the recommended initial treatment is a short-term, low-dose course of haloperidol or olanzapine. Hui et al. (2010) for example found olanzapine was given to 17% of delirious patients and haloperidol to 72% of the patients, perhaps reflecting the evidence that haloperidol has been shown to reduce symptoms of delirium in patients with cancer with no significant side effects (Akechi et al., 1996) .
Delirium is also one of the most common reasons patients with advanced cancer are prescribed sedation (Alonso-Babarro, VarelaCerdeira, Torres-Vigil, Rodriguez-Barrientos, & Bruera, 2010; Beller, van Driel, McGregor, Truong, & Mitchell, 2014) , which has been criticised on the basis that its use should be decided on an individual basis (National Ethics Committee, Veterans Health Administration, 2007).
The management of delirium requires an interdisciplinary approach (Meagher, 2001; Milisen et al., 2001 ) with nurses holding a key role in its prevention, detection and management (Siddiqi, House, & Holmes, 2006) (Anthony, LeResche, Niaz, Von Korff, & Folstein, 1982; Faught, 2014) . On the basis of the outcome, nurses can refer patients to the appropriate healthcare professionals for further assessment and treatment.
Despite the increasing amount of research into delirium experienced at the end of life in the past decade (Close & Long, 2012; Harris, 2007) , there are very few studies that focus on the treatment of delirium in patients with advanced cancer. A review of the evidence exploring the management of delirium in patients postsurgery and those being cared for in intensive care settings found delirium can be improved in around half of patients by removing precipitating factors (Kang, Shin, & Bruera, 2013) . Although this highlights some useful evidence for practice, the study did not specifically address the needs of patients with advanced cancer, where it is often not possible to eliminate some of the precipitating factors identified.
Patients who are at the end of their life as a result of advanced cancer are often receiving chemotherapy and opioid pain relief, which may mean the delirium experienced and the treatment for that delirium is different to that experienced by patients who do not have advanced cancer.
| Design
The design of this study is an integrative literature review. The purpose of nursing research is to solve problems or answer questions that are relevant to nursing practice (Polit & Beck, 2014) . The clinical management of delirium in patients with advanced cancer is one such problem. Although it is a common phenomenon (de la Cruz et al., 2015; Massie et al., 1983; Minagawa et al., 1996) , there is little guidance in practice concerning how best to manage it. The review question was developed using the Population, Intervention and Outcome elements of the PICO model (Polit & Beck, 2014) . This was used to guide the development of the question and because the focus was on studies reporting any intervention to alleviate delirium in patients with advanced cancer, the C (comparator) element was not required. This process is summarised in Table 2 .
An initial search revealed there was little research reporting the treatment of delirium in patients with advanced cancer. Consequently, although a systematic review is generally the recommended approach (Cullinan, 2005) , it was not appropriate for this question because of the variety of interventions explored in the relevant literature. In view of this and after discussions between HL and AH, it was decided that an integrative literature review should be undertaken. In contrast to a systematic reviews, which aim to systematically search for, appraise and synthesise research evidence, aiming for exhaustive and comprehensive searching (Grant & Booth, 2009 ) and adhere to a strict design based on explicit, prespecified and reproducible methods (Gopalakrishnan & Ganeshkumar, 2013) and generally focus on randomised controlled trials (Akobeng, 2005) , in an integrative of review, studies using diverse methodologies can be included and the approach has the potential to play a greater role in evidence-based practice for nursing (Whittemore & Knafl, 2005) . It is a review method which summarises previous empirical or theoretical literature, to provide a more comprehensive understanding of a healthcare problem (Broome 1993 [cited in Whittemore & Knafl, 2005 ). The primary sources included in an integrative review need to be logically grouped to facilitate analysis (Whittemore & Knafl, 2005) . Ryan (2013) recommends that the similarities and differences of the findings of different studies and patterns in the data should be explored and in the review reported here there were interventions that could be considered together.
| Search methods

Four databases; MEDLINE, CINAHL, ProQuest Nursing and Allied
Health and PsychInfo were searched because they were likely to include sources addressing the review question as they focus on medicine, nursing and psychology. The searches were conducted in April 2016 to include papers published in 2000 and later. Table 3 identifies the search terms used. The search terms were derived from the research question, and the databases were searched using those key words or phrases identified. Boolean operators (AND, OR, NOT) were used to further refine the search. A "wildcard" was also used, which allows multiple words to be searched for which have the same truncation, for example "deliri*" would return results for "delirium" and "delirious" (Averyard, 2010) . One article was found through hand-searching through the reference lists of relevant articles (Horsley et al., 2011) . Papers were excluded if they were unavailable in English, but not if they were conducted in other countries and reported in English. Both the search terms used and the databases where the searches were run were decided on by both HL and AH. The inclusion and exclusion criteria used to determine the selection of papers for review are shown in Table 4 .
| Search outcomes
The results of the screening process are shown in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) in Figure 1 below. The selection of the papers for inclusion in the review was made following independent review of titles and abstracts by both authors. Titles and abstracts were identified by the systematic search of the databases noted earlier, guided by the application inclusion and exclusion criteria (Table 4) . Papers found not to be relevant to the aims of study by their titles and abstracts were excluded. The full-text versions of the 27 papers which met the inclusion criteria were obtained and read. On the basis of this second stage of independent review, seven were found to be suitable for full critical review. Both AH and HL had read the papers and agreed that they were suitable for use in the study (Figure 1 ).
| Data abstraction
All the articles retrieved were read several times by one author and reviewed by the second author to gain a deeper understanding of the studies. A data abstraction form was used to record the key content of each paper in preparation for analysis (Polit & Beck, 2014) .
The design, aim sample, tool, results, limitations identified and recommendations made in the papers are summarised in Table 5 . 
| SUMMARY OF THE STUDIES INCLUDED
| CRITICAL APPRAISAL
The articles were then subjected to critical appraisal which involved assessing the strengths and weaknesses of the selected papers in T A B L E 4 Inclusion and exclusion criteria and rationale
Inclusion criteria Rationale
Patients with advanced cancer must make up the full or partial sample group 
Identification
Additional records identified through hand-searching (n = 1)
Records to be screened using title and abstract after duplicate removal (n = 479)
Duplicates excluded (n = 69)
Full-text articles assessed for eligibility (n = 27) Full-text articles excluded:
Focusing on prevention rather than treatment n = 12
Patients did not have advanced cancer n = 5
Case studies-n = 2 Conference paper n = 1
Studies included in literature review
Records excluded on basis of title and abstract (n = 452) order to assess their relevance to the review question (Averyard, 2010) . The papers were reviewed to assess trustworthiness and quality using a set of recognised criteria (Mhaskar et al., 2009; Polit & Beck, 2014) . The critical appraisal of the papers involved the use of a tool designed to assess the quality of studies employing a quantitative design (Hek & Moule, 2006) , supplemented with key questions developed by Polit and Beck (2014) . These were combined in an appraisal form which can be seen in Table 6 .
The appraisal of the specific statistical tests used in the studies can be seen in Table 7 (seen in the statistical analysis section below), and the overall quality ratings of the papers resulting from the application of the appraisal tool in Table 6 can be found in Table 8 .
| Synthesis
There is a lack of research which investigates delirium experienced by patients with advanced cancer and that which exists is of variable 6 | RESULTS
| Design
All of the studies lacked the rigour of RCTs, as they were open-label, nonblinded and nonrandomised (Sedgwick, 2014) , although most did report statistically significant results (apart from Moryl et al., 2005 which does not include any statistical analysis). All of the studies excepting Tatematsu et al. (2001) were prospective in nature.
| Sampling
The studies all used purposive sampling, a technique often used in qualitative research, where researchers select participants who can best address the purpose of the study (Averyard, 2010) . This type of sampling can introduce bias because of the absence of randomisation (Clifford, 1997) . However, in the studies reviewed here, the sample characteristics were so specific that it may have been difficult to recruit the patients in any other way. Excepting Breitbart et al. (2002) sample sizes were less than 30 (the 2010 study by Tatematsu used 31 patients for the control group and 17 for the intervention group) which affects the statistical significance of the findings (Krithikadatta, 2014) . Power calculations to determine the sample size required to test their hypothesis (Polit & Beck, 2014) were not carried out (or were not reported on), in the seven studies. 
| Tools
A number of tools were used to collect data about the presence and severity of delirium. The MDAS was the commonest (Boettger & Breitbart, 2011; Breitbart et al., 2002; Moryl et al., 2005) . The Japanese version, which omits some the original items, was used by Morita et al. (2005) . The CAM, DOS and MMSE were used in other studies (Arai et al., 2013; Gagnon et al., 2005; Tatematsu et al., 2001) . The use of different tools means identification of delirium varied between the studies. Those using MDAS applied different thresholds for the definition of delirium, for example Breitbart et al. (2002) , Boettger and Breitbart (2011) and Morita et al. (2005) considered an MDAS < 10 to indicate delirium resolution, whereas a score of less than 13 is generally accepted as accurate (Alici and Breitbart, n.d.) .
| Statistical analysis
All of the papers include statistical analysis of the results (producing inferential statistics) apart from Moryl et al. (2005) , which includes descriptive statistics. The statistical test used depends on the type of data, whether it is parametric or nonparametric, and then the type of data generated: nominal, ordinal, interval or ratio. Parametric data follow a normal distribution (usually a sample of 30 or more is required for this), and nonparametric data do not follow normal distribution (Krithikadatta, 2014) . A variety of statistical tests were used to analyse the data. Table 7 summarises the tests used and their appropriateness for the type of data they were analysing (Institute for Digital Research and Education, n.d.).
| MAIN TREATMEN T APPROACHES
| Atypical antipsychotics
The use of atypical antipsychotics was explored in two of the papers, olanzapine (Breitbart et al., 2002) and aripiprazole (Boettger & Breitbart, 2011) . Both report statistically significant results, with Boettger and Breitbart (2011) 
| Opioid rotation
Two studies explored opioid rotation in the management of delirium.
The change to methadone for patients with morphine-induced delirium (Moryl et al., 2005) and the replacement of morphine with fentanyl (Morita et al., 2005) . Moryl et al. (2005) found "average" MDAS improved from 23.6-10.6, but it is not specified if this is referring to the mean, mode or median. When fentanyl was introduced, the mean MDAS decreased from 14 at T1 to 3.6 at T3 (p < .001) (Morita et al., 2005) . However, the tool used to collect this data was the Japanese version of the MDAS, with some of the original items excluded, so again the results need to be regarded with caution.
| Other pharmacological interventions
Two studies reporting other pharmacological interventions were located. The first investigated the use of a coeliac plexus block (CPB), and it was found that the duration of terminal delirium (TD) was lower in the CPB group than the control group (1.8 AE 2.9 vs 10.4 AE 7.5 days respectively) (Arai et al., 2013) . In the second, methylphenidate hydrochloride was prescribed for patients with hypoactive delirium resulting in an improvement from 20.9 AE 4.9 pretreatment to 27.8 AE 2.4 on the MMSE when the patients were on a stable dose of methylphenidate . Its use for the treatment of hypoactive delirium in the study limits its generalisability to other forms of delirium.
| Nonpharmacological intervention
The only report of a nonpharmacological intervention located investigated the use of exercise therapy (Tatematsu et al., 2001) . It found that antipsychotic dose was lower in the experimental group (2.198 mg) than the control group (5.533 mg) (p < .036); however, the sample size was too small for the results to be generalisable. This study indicates there may be potential in nonpharmacological interventions as a wider range of staff would be able to deliver them.
| DISCUSSION
The findings of the research demonstrate that although there has been some investigation of the treatment of delirium in patients with advanced cancer, relatively few rigorous studies have been conducted. In terms of pharmacological interventions, the use of atypical antipsychotics reduced mean MDAS scores (Boettger & Breitbart, 2011; Breitbart et al., 2002) , as did opioid rotation (Morita et al., 2005 and Moryl et al., 2005) , a coeliac plexus block reduced the duration of terminal delirium (Arai et al., 2013) , and methylphenidate was found to be effective in patients with hypoactive delirium . The one report of a nonpharmacological intervention found that the dose of antipsychotics could be reduced for patients participating in exercise therapy (Tatematsu et al., 2001 ).
The findings of this literature review are inconclusive in terms of identifying a single safe and effective treatment for delirium experienced by patients with advanced cancer. Haloperidol is often the first-line treatment for delirium (NICE, 2010) ; however, a conference paper identified in the literature search reported that haloperidol alone was insufficient to control delirium in patients with advanced cancer because while 128 of the 167 patients required therapy with only haloperidol, 39 required a second neuroleptic to control symptoms (Susman, 2014) .
Another first-line treatment for delirium is olanzapine, which Breitbart et al. (2002) investigated and even though the rigour of the study is not comparable with an RCT, the results were still deemed to be significant. The use of aripiprazole has not been explored to a great extent although small studies such as the one by Boettger and Breitbart (2011) indicate it has helped resolve delirium. Further work is needed to determine whether it can be added to the drugs licensed to treat delirium.
The substitution of one opioid for another can improve therapeutic response and/or reduce side effects (Knotkova, Fine, & Portenoy, 2009; Morita et al., 2005; Moryl et al., 2005) . Patients with cancer often experience pain and are prescribed opioids for pain relief even though this increases the risk of delirium (Gaudreau, Gagnon, Roy, Harel, & Tremblay, 2007; Morrison et al., 2003) . Further investigation of the effects of opioid rotation is important for the treatment of delirium in patients with advanced cancer. The final pharmacological intervention studied was the use of methylphenidate hydrochloride in patients with hypoactive delirium . Methylphenidate is licensed to treat attention-deficit hyperactivity disorder (ADHD) (BNF, 2014) . It works by increasing the amount of dopamine available in areas of the brain responsible for reward and motivation (Volkow et al., 2012) and causes a "calming" effect on patients with ADHD. Because the pathophysiology of delirium is still not fully understood (Bush & Bruera, 2009) , it is not clear how methylphenidate works to improve symptoms. This suggests further trials of this agent would be of value.
The one nonpharmacological intervention studied was exercise therapy (Tatematsu et al., 2001) , which was found to be a useful adjunct to pharmacological treatment in mental health settings and is of relatively low cost (Daley, 2002) . Studies which explore nonpharmacological interventions are of particular interest to nurses, because if they are proven to be effective, they can be readily incorporated into the nursing management of patients with delirium. They are also useful because they can be investigated without the concomitant risk of adverse effects such as side effects or serious complications, anaphylactic shock for example, that can occur with pharmacological interventions (Cancer Research UK, 2015).
There remains limited information from randomised controlled trials of pharmacological agents to guide practice in evidence-based neuroleptic administration to cancer and palliative care patients (Bush & Bruera, 2009 ). Further research is needed to determine efficacious and safe drugs and dosages for the different delirium subtypes and aetiologies, as well as the role of nonpharmacological and environment management strategies in improving improve the comprehensive multifaceted management of this distressing syndrome (Bush & Bruera, 2009) .
With regard to the implications of the findings for clinical practice, it is important to consider options available to alleviate the distressing symptoms of delirium. Although treatments unlicensed for use in delirium such as aripiprazole and olanzapine cannot be introduced, interventions including exercise therapy could be considered.
Also the findings suggest that initiating discussions with doctors and pharmacists about the potential of opioid rotation is worthy of further exploration. In addition practicing in accordance with current guidelines for the care and treatment of delirium, including the provision of aides to orientation (for example having clocks and calendars visible in clinical areas), should remain a priority of care (NICE, 2010).
| Limitations
As with any literature review, this one has limitations. For example, unpublished or "grey" literature was not included which has the potential to introduce publication bias, in that journals tend to favour articles which report positive results, leading to overrepresentation of significant findings (Cullinan, 2005; Polit & Beck, 2014) . Also in view of the type of interventions used in the treatment of delirium the nature of the studies reported varied, an integrated approach was taken because a meta-analysis was not possible.
| CONCLUSION
Delirium is a poorly understood condition which is frequently experienced by patients with advanced cancer; however, there is limited knowledge of its pathophysiology, particularly of its subtypes. The findings from the seven studies examined in this review do not provide a conclusive evidence base for the treatment of delirium for patients with advanced cancer, although the interventions seemed to have some impact in terms of reducing the severity or the duration of the delirium.
However, despite the lack of evidence on which to make definitive recommendations about treatment and care, the current gap in knowledge has been identified, and there appear to be some promising areas for further research. More work is needed to build understanding of the pathophysiology of delirium in patients with advanced cancer, and once this is more widely understood, there can be more informed research into its treatment. Ideally, this should take the form of randomised controlled trials that can take account of confounding factors including age, cotreatments and cancer diagnosis (stage and tumour site) so that the effect of these factors can be analysed, so the true reason for delirium resolution can be identified.
CONTRIBU TI ONS
Study design: HL, AH; data collection and analysis: HL, AH; and manuscript preparation: HL, AH.
CONF LICT OF I NTEREST
No conflict of interest has been declared by the author(s).
